Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31634394 | 1.00 | CNR1 (0.41) | CNR1USP30CNR2STSGPR119 | |
| SCHEMBL30960352 | 0.88 | YEATS4 (0.36) | HSD17B10 | |
| SCHEMBL27349808 | 0.84 | GPR119 (0.42) | CNR1USP30CNR2STSGPR119 | |
| SCHEMBL27349793 | 0.84 | GPR119 (0.42) | CNR1USP30CNR2STSGPR119 | |
| SCHEMBL31727646 | 0.84 | GPR119 (0.42) | CNR1USP30CNR2STSGPR119 | |
| SCHEMBL27349821 | 0.77 | STS (0.42) | CNR1USP30CNR2STSGPR119 | |
| SCHEMBL16763620 | 0.76 | FPR2 (0.49) | CNR1STSGPR119MAPK8MEN1 | |
| SCHEMBL16513097 | 0.76 | FPR2 (0.49) | CNR1STSGPR119MAPK8MEN1 | |
| SCHEMBL27349800 | 0.76 | ALOX15 (0.41) | CNR1USP30CNR2STSMAPK8 | |
| SCHEMBL30960359 | 0.75 | MMP7 (0.39) | USP30SMN1; SMN2MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208997-A1 | CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS | CGAS, STING1, IFNAR1 | CNR1 1970/4885USP30 4096/4885CNR2 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.